HitGen is a technology-driven company with headquarters and main research facilities based in Chengdu, China and with offices in the USA. HitGen has established a platform for small molecular discovery centred around DNA encoded chemical libraries (DELs) . HitGen’s DELs contain more than 100 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies and research institutes in Asia, North America and Europe to discover and develop approaches for novel medicines and agrochemical solutions.